ASCO22: dabrafenib plus trametinib shows increased response rates in pediatric low-grade gliomas

A novel oral targeted therapy combination, dabrafenib plus trametinib, has demonstrated significantly increased overall response rates (ORR) in pediatric BRAF V600 mutation-positive low-grade gliomas compared to standard-of-care chemotherapy. Recently presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (3–6 June; Chicago, IL, USA), the findings also showed an improved clinical benefit rate and prolonged progression-free survival (PFS) for the new combination. The study was a double-blind Phase II/III clinical trial conducted at 57 investigative centers in 20 countries, which randomly assigned 110 patients from ages 1–17, who had BRAF V600 mutation-positive low-grade gliomas to either the dabrafenib...